ChartMillAugust 6, 2026 at 8:02 PM NY2 Months Ago
CytomX Therapeutics (NASDAQ:CTMX) Shares Plunge After Q2 Revenue and EPS Miss Estimates
Cytomx (CTMX) shares fell ~30% after Q2 revenue and EPS missed estimates. Lead program Varseta-M Phase 1 data expected by end of 2026.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: ChartMill
